Article Information
History
- February 21, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Marjut Sarjomaa1,2,*,
- Lien My Diep3,
- Chi Zhang3,4,
- Yngvar Tveten5,
- Harald Reiso6,
- Carina Thilesen7,
- Svein Arne Nordbø8,9,
- Kristine Karlsrud Berg10,
- Ingeborg Aaberge4,
- Neil Pearce11,
- Hege Kersten12,13,
- Jan Paul Vandenbroucke11,14,15,
- Randi Eikeland16,17 and
- Anne Kristin Møller Fell2,17
- 1Department of Infection Control, Telemark Hospital Trust, Skien Norway
- 2Department of Community Medicine and Global Health and Society, University of Oslo, Norway
- 3Oslo Centre for Biostatistics and Epidemiology, Oslo, Norway
- 4Norwegian Institute of Public Health, Oslo, Norway
- 5Department of Clinical Microbiology, Telemark Hospital Trust, Skien, Norway
- 6The Norwegian National Advisory Unit on Tick-borne Diseases, Sørlandet Hospital Trust, Arendal
- 7Unilabs Laboratory Medicine, Skien, Norway
- 8Department of Medical Microbiology, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway
- 9Norwegian University of Science and Technology, Trondheim, Norway
- 10Department of Medical Microbiology, Sørlandet Hospital Trust, Kristiansand, Norway
- 11London School of Hygiene and Tropical Medicine, London, United Kingdom
- 12Department of Research, Telemark Hospital Trust, Norway
- 13School of Pharmacy, University of Oslo, Norway
- 14University of Leiden, Leiden, Netherlands
- 15University of Aarhus, Aarhus, Denmark
- 16Department of Health and Nursing Science, University of Agder, Grimstad, Norway
- 17Department of Occupational and Environmental Medicine, Telemark Hospital Trust, Skien, Norway
- ↵*Corresponding author: Email: sarm{at}sthf.no (MS)
Posted February 21, 2022.
SARS-CoV-2 antibody persistence after five and twelve months: A cohort study from South-Eastern Norway
